

School of Clinical Medicine Department of Family Medicine vied & Primary Care 香港大學家庭醫學及基層醫療學系













BIG-DATA PHARMACOVIGILANCE OF COVID-19 VACCINES SHAPES PUBLIC HEALTH POLICIES

以大數據對新冠疫苗效用及安全性的監察幫 助制訂公共衞生政策




Prof Esther Chan Dr Celine Chui Dr Francisco Lai Dr Shirley Li Dr Eric Wan Dr Carlos Wong Prof Ian Wong



COVID-19 Vaccines Adverse Events Response and Evaluation (CARE) Programme






Summary of impact

- Science:
 - Linked up population-based records to identify potential adverse events after COVID-19 vaccination
 - Among the first teams in the world to analyze Bell's palsy and carditis following vaccination
- Impact on patients and practice:
 - DH accepted our findings- Bell's palsy as an adverse effects of CoronaVac
 - Pay out compensation to vaccine recipient.
 - Amendment of the product insert.
 - Based on our finding of BNT162b2 and carditis:
 - Suspension of the 2nd dose of BNT162b2 for minors
 - Then extended the duration of second dose from 4 weeks to 8 weeks.
 - Issue warnings of carditis to alert patients and healthcare professional



Impacts to Hong Kong


- Policy impact-Fulfillment of CAP 599K: Our team monitors adverse events of COVID-19 vaccines on behalf of Drug Office of the DH so that DH can comply with CAP599K Part 3:7(3)
- Research impact-Established model for pharmacovigilance:
 - Territory-wide public healthcare database (Hospital Authority) linked with populationbased vaccination records and COVID infection records. (Department of Health) No precedent case, history was made.





The CARE Programme is a comprehensive surveillance programme implemented under The University of Hong Kong Department of Pharmacology & Pharmacy Team that closely monitors known and potential adverse events of COVID-19 vaccines. It aims to ascertain details of adverse events and inform the public in a timely manner.





Underpinning Research (1) Bell's palsy following CoronaVac

- Nested case-control study
- 298 cases of Bell's palsy were matched to 1,181 controls, and the adjusted odd ratio (OR) was <u>2.4 (95% CI:1.4-4.0) for</u> <u>CoronaVac</u>
- The Lancet Infectious Diseases (Impact Factor = 71) <u>https://doi.org/10.1016/S1473-3099(21)00451-5</u>

	ANCET us Diseases	Log in	Register	Subr	scribe	Claim	Q	≡
<	MERCLES COLLINE THEFT Bell's palsy following vaccination with mRM (CoronaVac) SARS-CoV-2 vaccines: a case so study Inc Vac Fai Way, PhD ⁻¹ - Online Sar Ling Chai, PhD ⁻¹ - Francisco Fair Sar Li, PhD - Vecent Ka Chair Yay, BPharm - et al. Show all actions Published: August 36, 2021 - DOR: https://doi.org/10.1026/53.023	eries and nest	?) and ina ted case-t	ontro		D		~
Tunnary Introduction Methods	Summary Background		n	11		100 million (100 million)	quest Yo fored Ac	the second se

World-wide press-release by Lancet Press Centre



Embargo: 23.30 [UK time] Monday 16th August 2021Please add pressoffice@lancet.com to your safe senders list to ensure that you always receive The Lancet press releases.

Embargo: 23.30 [UK time] Monday 16th August 2021

Peer-reviewed / Observational / People


The Lancet Infectious Diseases: Benefits of COVID-19 vaccines far outweigh very rare risk of Bell's palsy, study confirms

 Study is the first large-scale population analysis of the risk of Bell's palsy following vaccination with CoronaVac (Sinovac Biotech vaccine, an inactivated vaccine) or BNT162b2 (Fosun-BioNTech, equivalent to Pfizer-BioNTech vaccine, an mRNA From: https://www.COVIDvaccine.gov.hk/pdf/CO VID19VaccinationFactSheet_CoronaVac_E NG.pdf

4 Possible side effects¹

	Side effects	may affect			
Very common	injection site: painheadachefatigue	≥ 10% people			
Common	 injection site swelling, pruritus, erythema, induration myalgia nausea diarrhea arthralgia cough chills pruritus loss of appetite rhinorrhea sore throat nasal congestion abdominal pain 	1% -10% people			
Uncommon	 burn at injection site vomit hypersensitivity abnormal skin and mucosa fever tremor flushing edema dizziness drowsiness 	0.1% -1% people			
Rare	Rare• muscle spasms • eyelid edema • nosebleeds • abdominal distension • constipation• ocular congestion • hot flashes • hiccup • conjunctival congestion				
Very rare	 Bell's palsy[#] [#]Observed post-authorisation in Hong Kong 	<0.01% people			
Serious	Serious • No serious adverse event related to vaccination was identified up to 3 February 2021.				






Summary of impact

- Science:
 - Linked up population-based records to identify potential adverse events after COVID-19 vaccination
 - Among the first teams in the world to analyze Bell's palsy and carditis following vaccination
- Impact on patients and practice:
 - DH accepted our findings- Bell's palsy as an adverse effects of CoronaVac
 - Pay out compensation to vaccine recipient.
 - Amendment of the product insert.
 - Based on our finding of BNT162b2 and carditis:
 - Suspension of the 2nd dose of BNT162b2 for minors
 - Then extended the duration of second dose from 4 weeks to 8 weeks.
 - Issue warnings of carditis to alert patients and healthcare professional





Underpinning Research (2) Elevated risk of carditis following BNT162b2

- Territory-wide case—control study
- BNT162b2 recipients had higher odds of carditis (adjusted OR, 3.57 [CI, 1.93 to 6.60])
 - Male: OR 4.68 (CI, 2.25 to 9.71)
 - Female: OR 2.22 (CI, 0.57 to 8.69)
 - Adults OR 2.41 (CI, 1.18 to 4.90)
 - Adolescents OR 13.79 (CI, 2.86 to 110.38)
- Risk mainly seen after the 2nd dose
- Annals of Internal Medicine (Impact Factor = 51) https://doi.org/10.7326/M21-3700

Annals of Internal Medicine

0 0

Original Research | 25 January 2022

Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine 🚥


A Case-Control Study

Francisco Tiz Toun Lai, PhD* 😳, Xue Li, PhD* 😳, Kuan Peng, MHS, Lei Huang, MSc, Patrick Ip, MPH, Xinning Tong, PhD, Celine Sze Ling Chui, PhD 🤤

Eric Yuk Fai Wan, PhD 🥥, Carlos King Ho Wong, PhD 🔕, Eitther Wai Yin Chan, PhD 🥝, David Chung Wah Siu, MD 🤤, Ian Chi Kei Wong, PhD 🚭 Wey authors 🗙 Author, Article and Discloture Information

https://doi.org/10.7326/M21-3700 Eligible for CME Point-of-Care






Underpinning Research (2) Overall safety of and risk of myocarditis following BNT162b2 in adolescents

		JACC	All Journals 🗸 Enter Search Terms	
😂 Taylor, Francis Online	🚨 Log in Register 🏾 🍞 Cart	Journals V Topics V Guidelines V A	Author Center v CME/MOC v Events v JACC Patien	
Home ► All Journals ► Emerging Microbes ► List of Issues ► Latest Articles ► Adverse	Events of S	Journal of the American College	of Cardiology	
Emerging Microbes & Infections >		Journal of the American College	of cardiology	
Latest Articles	nature communications		Next	
Open access	nature communications			
713 0 4 Views CrossRef citations to date Altmetric	Explore content ∽ About the journal ∽ Publish w	ith us 🗸	nRNA COVID-19 Vaccination Compared With	
4) Listen 🕨				
Research Article	<u>nature</u> > <u>nature communications</u> > <u>articles</u> > article			
Adverse Events of Special Interest Followin			Lung Cheung, Celine Sze Ling Chui, Xue Li, Eric Yuk Fai Wan,	
in Adolescents: A Population-Based Retrosp Francisco Tsz Tsun Lai PhD, Gilbert T Chua MBBS, Edward Wai Wa Chan MPH, Lei Huang M			in Chi Kei Wong	
Tiantian Ma PhD,show all	Effectiveness of BNT162b2 afte			
Accepted author version posted online: 07 Mar 2022.	series dosing interval in childre	leassurance in an Era of Dynamic Uncertainty		
Download citation Download citation Phttps://doi.org/10.1080/22221751.2022.2050952 Download citation	5-17			
Full Article Figures & data # References O Supplemental # Citations M Metrics O Lice	Francisco Tsz Tsun Lai, Min Fan, Caige Huang, Celine Sze Li	ng Chui Frie Yuk Fai Wan, Yua Li, Carlos King Ha		
	Wong, Ching-Lung Cheung, Ian Chi Kei Wong [™] & Esther ¹			
PDF EPUB	wong, <u>ching-tang cheang</u> , <u>ian chi kerwong</u> — & <u>isther</u>			
Accepted author version	Nature Communications 14, Article number: 1845 (2023)	<u>Cite this article</u>		
Concepted autor version	1523 Accesses 23 Altmetric Metrics			

C ITACC





The Government of the Hong Kong Special Administrative Region Press Releases									
GovHK 香港政府一	站通	繁體版	简体版						

Government adjusts COVID-19 vaccination requirem ¥






Government adjusts COVID-19 vaccination requirement under social distancing measures according to expert advice

The Government announced today (September 30) that in accordance with the advice of the Advisory Panel on COVID-19 Vaccines, from today onwards, persons aged 12 to 17 who have received one dose of Fosun Pharma/BioNTech COVID-19 vaccine (Comirnaty vaccine) at least 14 days ago are deemed to have complied with the requirement of completing the COVID-19 vaccination course under the Prevention and Control of Disease (Requirements and Directions) (Business and Premises) Regulation (Cap. 599F).






Summary of impact

- Science:
 - Linked up population-based records to identify potential adverse events after COVID-19 vaccination
 - Among the first teams in the world to analyze Bell's palsy and carditis following vaccination
- Impact on patients and practice:
 - DH accepted our findings- Bell's palsy as an adverse effects of CoronaVac
 - Pay out compensation to vaccine recipient.
 - Amendment of the product insert.
 - Based on our finding of BNT162b2 and carditis:
 - Suspension of the 2nd dose of BNT162b2 for minors
 - Then extended the duration of second dose from 4 weeks to 8 weeks.
 - Issue warnings of carditis to alert patients and healthcare professional






Effective engagement: Regulatory Authority and general public

- Direct Reports to DH for action
 - relevant public health policies and clinical recommendations
- Press Conferences
 - Sending reassurance to the public
 - Provide the best possible information to inform vaccine uptake
- Training course for DH staff
 - Offer training for public health policy makers








Long lasting impact on pharmacovigilance in Hong Kong

- Based on the success of CARE programme, our HKUMed team have demonstrated the untapped power of HA and DH databases.
 - It broke down the previous invisible barrier of data linkage.
- Drug office of DH is currently developing a new system in pharmacovigilance based on CARE programme and will continue to work with our team to create the next generation pharmacovigilance system.






Knowledge to be Exchanged

- Identifying rare adverse events following COVID-19 vaccines which would otherwise be infeasible to detect
- Establishing a comprehensive safety profile of COVID-19 vaccines
- Developing data-linkage mechanisms for future pharmacovigilance purposes
- Innovating and refining pharmacoepidemiologic methods in vaccine safety monitoring





Thank you

